Can low folate, vitamin B12, and magnesium despite supplementation indicate absorption or utilization problems?

Pathophysiological mechanisms and genetic barriers

• Impaired remethylation pathway: Insufficient levels of folate and vitamin B12 block the conversion of homocysteine back to methionine. Methylcobalamin and 5-methyltetrahydrofolate (5-MTHF) are mandatory cofactors in this enzymatic process; their depletion directly drives hyperhomocysteinemia.
• Genetic polymorphisms: Individuals carrying the MTHFR C677T variant experience significantly reduced enzyme activity. This limits the biological conversion of standard dietary or supplemental folic acid into active 5-MTHF, representing a critical nutrient form mismatch.

Absorption and pharmacological barriers

• Gastrointestinal malabsorption: Conditions like celiac disease compromise the proximal small bowel, directly impairing folate and magnesium uptake. Autoimmune atrophic gastritis and pernicious anemia deplete gastric acid and intrinsic factor, preventing adequate vitamin B12 cleavage and absorption.
• Drug-induced depletion: Chronic use of proton pump inhibitors (PPIs) suppresses gastric acid, which impairs the release of food-bound B12 and compromises magnesium absorption mechanisms. Additionally, increased systemic utilization or renal wasting of magnesium (such as from loop diuretics) can easily outpace standard oral dosing.

Bottom line

• Persistently low folate, B12, and magnesium alongside elevated homocysteine despite oral supplementation indicate underlying gastric malabsorption, genetic variants like MTHFR, drug-nutrient interactions, or formulation mismatches. Resolving these deficiencies requires utilizing active-form nutrients (such as 5-MTHF) or parenteral therapies to bypass compromised absorption pathways.